This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Dosimetric Variability Across a Library of Computational Tumor Phantoms
- Dosimetry in Radiopharmaceutical Therapy
- ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
- First Whole-Body Three-Dimensional Tomographic Imaging of Alpha Particle Emitting Radium-223
- In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
- Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma
- Utilizing High-Energy {gamma}-Photons for High-Resolution 213Bi SPECT in Mice
- Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody
- Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells
- Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
- Immunoliposomal Delivery of 213Bi for {alpha}-Emitter Targeting of Metastatic Breast Cancer
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of {alpha}-Particle Emitters for Targeted Radionuclide Therapy
- Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted {alpha} Radioimmunoconjugates
- 213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model
- Uncertainties in Internal Dose Calculations for Radiopharmaceuticals
- Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry
- Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia
- Nuclear Localizing Sequences Promote Nuclear Translocation and Enhance the Radiotoxicity of the Anti-CD33 Monoclonal Antibody HuM195 Labeled with 111In in Human Myeloid Leukemia Cells
- A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies
- Absorbed Fractions for {alpha}-Particles in Tissues of Trabecular Bone: Considerations of Marrow Cellularity Within the ICRP Reference Male
- Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
- Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease
- Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers
- Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression
- Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
- Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection
- Engineered Liposomes for Potential {alpha}-Particle Therapy of Metastatic Cancer
- Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection
- Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer
- Microdosimetric Analysis of {alpha}-Particle-Emitting Targeted Radiotherapeutics Using Histological Images
- Targeted alpha particle immunotherapy for myeloid leukemia
- Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- High-Level Production of {alpha}-Particle-Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use
- Comparative Cellular Catabolism and Retention of Astatine-, Bismuth-, and Lead-Radiolabeled Internalizing Monoclonal Antibody
- Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)
- Parametric Images of Antibody Pharmacokinetics in Bi213-HuM195 Therapy of Leukemia
- An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer